ContributorsPublishersAdvertisers

Cellular Therapy Strategies Offer the Prospect of Deep Remissions for Multiple Myeloma

onclive.com
 2021-10-08

The FDA approval of the first chimeric antigen receptor T-cell therapy in March 2021 for the treatment of relapsed/refractory multiple myeloma represents a significant advance. For more than a decade, we’ve been able to approach multiple myeloma, in most cases, as a chronic disease treatable through long-term maintenance therapy....

www.onclive.com

Comments / 0

Comments / 0